CN109641882B - 作为nik抑制剂的杂芳族衍生物 - Google Patents

作为nik抑制剂的杂芳族衍生物 Download PDF

Info

Publication number
CN109641882B
CN109641882B CN201780053583.6A CN201780053583A CN109641882B CN 109641882 B CN109641882 B CN 109641882B CN 201780053583 A CN201780053583 A CN 201780053583A CN 109641882 B CN109641882 B CN 109641882B
Authority
CN
China
Prior art keywords
alkyl
substituted
het
substituents
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780053583.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641882A (zh
Inventor
I·斯坦斯菲尔德
O·A·G·奎伊罗勒
Y·A·E·里格奈
格哈德·马克斯·格罗斯
埃德加·雅各比
L·米尔波尔
西蒙·理查德·格林
G·海恩德
J·J·库拉戈维斯基
C·马克勒奥德
S·E·马恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN109641882A publication Critical patent/CN109641882A/zh
Application granted granted Critical
Publication of CN109641882B publication Critical patent/CN109641882B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780053583.6A 2016-06-30 2017-06-29 作为nik抑制剂的杂芳族衍生物 Active CN109641882B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16177104.3 2016-06-30
EP16177104 2016-06-30
PCT/EP2017/066120 WO2018002217A1 (en) 2016-06-30 2017-06-29 Heteroaromatic derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
CN109641882A CN109641882A (zh) 2019-04-16
CN109641882B true CN109641882B (zh) 2022-10-28

Family

ID=56296645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053583.6A Active CN109641882B (zh) 2016-06-30 2017-06-29 作为nik抑制剂的杂芳族衍生物

Country Status (9)

Country Link
US (1) US11136311B2 (enExample)
EP (1) EP3478675B1 (enExample)
JP (1) JP6936815B2 (enExample)
KR (1) KR102517352B1 (enExample)
CN (1) CN109641882B (enExample)
AU (1) AU2017289315B2 (enExample)
CA (1) CA3027416A1 (enExample)
ES (1) ES2805976T3 (enExample)
WO (1) WO2018002217A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012031C (en) 2016-01-22 2024-03-26 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
US11180487B2 (en) 2016-01-22 2021-11-23 Janssen Pharmaceutica Nv Substituted cyanoindoline derivatives as NIK inhibitors
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP6936815B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としてのヘテロ芳香族誘導体
JP7301958B2 (ja) 2018-05-25 2023-07-03 オンコキューブ セラピューティクス エルエルシー 新規な抗がん薬候補としての非常に強力なtacc3阻害剤
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
AU2019203034B1 (en) * 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
MX2021014679A (es) 2019-05-31 2022-04-06 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb.
WO2020258006A1 (en) 2019-06-25 2020-12-30 Inventisbio Shanghai Ltd. Heterocyclic compounds, preparation methods therefor, and methods of uses thereof
KR20210002015A (ko) 2019-06-27 2021-01-06 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN117460724A (zh) * 2021-04-12 2024-01-26 A2A制药有限公司 用于治疗癌症的组合物和方法
KR20250005157A (ko) 2022-03-24 2025-01-09 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN105579451A (zh) * 2013-09-26 2016-05-11 詹森药业有限公司 作为NIK抑制剂的新型1-(4-嘧啶基)-1H-吡咯并[3,2-c]吡啶衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
ES2608670T3 (es) 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
CN103732067A (zh) 2011-04-12 2014-04-16 美国阿尔茨海默病研究所公司 化合物,组合物及它们的治疗用途
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CA2922657C (en) 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
EP3489232A3 (en) 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2017520526A (ja) 2014-05-22 2017-07-27 ザ・ユニバーシティ・オブ・シドニー オメガ−3類似体
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
CN106715419A (zh) * 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
US11180487B2 (en) 2016-01-22 2021-11-23 Janssen Pharmaceutica Nv Substituted cyanoindoline derivatives as NIK inhibitors
CA3012031C (en) 2016-01-22 2024-03-26 Janssen Pharmaceutica Nv 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
JP6936815B2 (ja) 2016-06-30 2021-09-22 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としてのヘテロ芳香族誘導体
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN105579451A (zh) * 2013-09-26 2016-05-11 詹森药业有限公司 作为NIK抑制剂的新型1-(4-嘧啶基)-1H-吡咯并[3,2-c]吡啶衍生物

Also Published As

Publication number Publication date
AU2017289315A1 (en) 2019-01-24
KR20190025644A (ko) 2019-03-11
JP6936815B2 (ja) 2021-09-22
US11136311B2 (en) 2021-10-05
JP2019521097A (ja) 2019-07-25
AU2017289315B2 (en) 2021-04-01
EP3478675A1 (en) 2019-05-08
WO2018002217A1 (en) 2018-01-04
ES2805976T3 (es) 2021-02-16
KR102517352B1 (ko) 2023-03-31
CA3027416A1 (en) 2018-01-04
EP3478675B1 (en) 2020-04-22
US20190359598A1 (en) 2019-11-28
CN109641882A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
CN109641882B (zh) 作为nik抑制剂的杂芳族衍生物
CN108697710B (zh) 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物
CN109311846B (zh) 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物
CN109689645B (zh) 作为nik抑制剂的氰基吲哚啉衍生物
TW201602103A (zh) 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
CN107074881A (zh) 作为nik抑制剂的新的噻吩并嘧啶衍生物
CN110831940B (zh) 作为nik抑制剂的新取代的氮杂吲哚啉衍生物
CN107108634A (zh) 作为PI3Kβ抑制剂的咪唑并哒嗪衍生物
RU2780577C2 (ru) Новые замещенные производные азаиндолина в качестве ингибиторов nik
HK1261385B (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1261385A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1224295B (en) New 1-(4-pyrimidinyl)-1 h-pyrrolo(3,2-c) pyridine derivatives as nik inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant